Serum-free cell culture media provide a reliable and standardized alternative to traditional serum-based systems by eliminating the variability associated with human AB serum or fetal calf serum (FCS). By using defined formulations, researchers can achieve consistent, reproducible results without the unpredictability of serum batches.
Conventional serum-based media often require extensive pre-screening due to batch-to-batch variability, which can significantly impact experimental outcomes. Even brief exposure of PBMC (Peripheral Blood Mononuclear Cells) to unsuitable serum can lead to high background signals in cytokine assays or compromised cell viability. Additionally, toxic or inhibitory serum batches can negatively affect assay performance, increasing both cost and complexity.
Serum use also introduces biosafety concerns and regulatory challenges, particularly for international transport and material exchange. These limitations have driven the scientific community toward adopting defined, serum-free alternatives that improve consistency while reducing risk.
To address these challenges, CTL (Cellular Technology Limited) has developed a comprehensive Serum-Free Media Platform, designed specifically for sensitive applications involving human PBMC. Developed in collaboration with government, academic, and industrial partners, this platform ensures optimal cell viability and functionality across all stages of sample handling.
The CTL platform includes specialized media solutions that support the four critical steps of PBMC workflows:
- Washing
- Testing
- Freezing
- Thawing
By replacing serum in each of these steps, CTL’s serum-free media deliver enhanced assay reliability, improved reproducibility, and streamlined workflows, making them ideal for immunology research, vaccine development, and cell-based assays.
Labindia Instruments Pvt. Ltd. is the authorised dealer in India for CTL (Cellular Technology Limited), providing trusted solutions and expert support for advanced cell culture applications.
